Oncology

Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

Targeted therapies have greatly improved patient outcomes over the past 20 years.

Trends in treatment development involve more targeted, safe, and efficacious therapies.

Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.

The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Identifying how survivors adjust to their cancer may help health care providers provide tailored self-management skills.

The median progression-free survival and overall survival were 7.4 and 14.7 months, respectively, in chemotherapy-naïve patients with advanced or recurrent biliary tract cancer.

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

Merck and Moderna’s adjuvant melanoma treatment shows reduced risk of recurrence or death by 44% compared with pembrolizumab alone.

E7777 is an engineered interleukin-2-diphtheria toxin fusion protein that is a purified and more bioactive formulation of Ontak, which the agency previously approved.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.

Despite a limited understanding about access to oral anticancer drugs, new research finds challenges in patient and clinician decision-making.

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

The FDA clinical reviewer responsible for the approval of this combination therapy discusses the data that led to the approval in May 2022.

Phase 1 clinical trial data show the drug to be active with evidence of clinically meaningful responses and a manageable safety profile.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.

The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.

BYLieve clinical trial data indicate long-term and very-long-term data disease control was observed in 25.6% and 16.5% of patients, respectively, with PFS at 24.8 and 29.4 months in patients with HR-positive, HER2-negative advanced breast cancer.